On December 13, 2022, the COVID-19 vaccine developer Moderna and pharmaceutical company Merck announced a progressive advancement in forming vaccination for melanoma, known as one of the most fatal types of skin cancer.
Moderna is collaborating with Merck to study and create a feasible melanoma vaccine among patients who had surgery for their cancer. The study combines an mRNA vaccine strategy and a drug to expedite the immune system and bring favorable results for melanoma patients.
With the vaccine and Merck's immunotherapy Keytruda, the team saw a notable difference in the patient's survival rate. “We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” shared Moderna CEO Stephane Bancel with CNBC. Phase 3 is typically the most costly stage of research before the drug gets officially approved.
/Passle/60211dc9e5416a0c14bc63d4/SearchServiceImages/2026-10-09-14-47-29-978-6ac8fe81bf2cf47546e7c7c8.jpg)
The global issues we face are challenging and interconnected. They can seem insurmountable. But if you know where to look, co-operation, positive change and hope are all around us. Build Beyond Ever Better is a project that recognises the progress being made, and the amazing people who are making a difference. Share your own hopes, pledges and projects with #BBEB, or become a contributor.
Please read our BBEB Charter.
/Passle/60211dc9e5416a0c14bc63d4/SearchServiceImages/2026-10-16-15-04-20-057-6ad23cf4b378b0c78cece71b.jpg)
/Passle/60211dc9e5416a0c14bc63d4/SearchServiceImages/2026-10-16-11-16-08-226-6ad20778f0722e0f6fffd010.jpg)
/Passle/60211dc9e5416a0c14bc63d4/SearchServiceImages/2026-10-22-14-57-06-228-6ada2442594ea8e6e3b00785.jpg)
